Radiotherapy combined with cetuximab for locally advanced head and neck cancer: Results and toxicity

Cancer/Radiotherapie

Volumn 16, Issue 7, 2012, Pages 601-603

  Acevedo Henao, C M ^a,b   Valette, G ^a   Miglierini, P ^a   Lefur, E ^a   Pradier, O ^a  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b FUNDACIÓN VALLE DEL LILI   (Colombia)

Author keywords

Cetuximab; Head neck cancer; Radiotherapy

Indexed keywords

CETUXIMAB; HEMOGLOBIN;

ACNE; ACUTE CORONARY SYNDROME; ADULT; ADVANCED CANCER; APLASIA; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX SQUAMOUS CELL CARCINOMA; LUNG INFECTION; LYMPH NODE METASTASIS; MALE; MOUTH SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION INJURY; RESPIRATORY DISTRESS; SEPSIS; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; XEROSTOMIA;

ACNE VULGARIS; ANAPHYLAXIS; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CRANIAL IRRADIATION; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; GASTROSTOMY; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUCOSITIS; PROTEIN KINASE INHIBITORS; RADIODERMATITIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84868459113     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2012.06.005     Document Type: Article

References (10)

1. Argiris A., Karamouzis M.V., Raben D., Ferris R.L. Head and neck cancer. Lancet 2008, 371:1695-1709.
2. Haddad R.I., Shin D.M. Recent advances in head and neck cancer. N Engl J Med 2008, 359:1143-1154.
3. Bourhis J., Lefebvre J.L., Vermorken J.B. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?. Eur J Cancer 2010, 46:1979-1989.
4. Oksuz D.C., Prestwich R.J., Carey B., Wilson S., Senocak M.S., Choudhury A., et al. Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy. Radiat Oncol 2011, 6:54.
5. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
6. Pignon J.P., le Maitre A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
7. Bonner J.A., Harari P.M., Giralt J., Cohen R.B., Jones C.U., Sur R.K., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
8. Bozec A., Thariat J., Bensadoun R.J., Milano G. Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies. Cancer/Radiother 2008, 12:14-24.
9. Hoff C.M., Hansen H.S., Overgaard M., Grau C., Johansen J., Bentzen J., et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiother Oncol 2011, 98:28-33.
10. Chua W., Peters M., Loneragan R., Clarke S. Cetuximab-associated pulmonary toxicity. Clin Colorectal Cancer 2009, 8:118-120.